Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

210
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
210
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

213
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
213
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

199
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
199
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

308
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
308

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inter-Observer Variability of Gerd-Related Metrics on High-Resolution Manometry and Calculation of the Milan Score.

Neurogastroenterology and motility·2026
Same author

Double immunohistochemistry to detect transglutaminase 2-IgA deposits in celiac children: a multicentre study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same author

Dupilumab for Eosinophilic Esophagitis in Adolescents and Adults: Real-World Outcomes Across Different Dosing Regimens from the EoE CONNECT Registry.

The American journal of gastroenterology·2026
Same author

An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients.

Therapeutic advances in gastroenterology·2026
Same author

The Immune Architecture of Eosinophilic Esophagitis: Mechanisms, Therapeutic Targets, and Precision Management.

ImmunoTargets and therapy·2026
Same author

Chronic Liver Disease, Liver Damage and Liver Failure After Hypoabsorptive Bariatric Surgery: A Dose-Dependent Relationship and Multisystemic Consequences.

European journal of clinical investigation·2026

Related Experiment Video

Updated: Jul 19, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

804

Clopidogrel-Induced Eosinophilic Colitis.

Shirin Djahandideh Sheijani1,2, Francesco Calabrese1,2, Andrea Pasta1,2

  • 1Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.

ACG Case Reports Journal
|August 7, 2023
PubMed
Summary

Eosinophilic colitis, a rare gut condition, can be triggered by medications. This case highlights clopidogrel as a potential cause, with symptoms resolving after drug discontinuation.

Keywords:
antiplatelet drugseosinophilic gastrointestinal diseasehistology

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.1K

Related Experiment Videos

Last Updated: Jul 19, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

804
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.1K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Histopathology

Background:

  • Eosinophilic colitis is a rare gastrointestinal disorder defined by eosinophil infiltration in the gut wall.
  • Its etiology is often unclear, with potential links to infections, drugs, and immune-mediated diseases.

Observation:

  • A patient presented with chronic, worsening diarrhea and abdominal pain.
  • Diagnostic colonoscopy with biopsies revealed eosinophilic colitis.

Findings:

  • The patient's eosinophilic colitis was diagnosed as secondary to clopidogrel use.
  • Discontinuation of clopidogrel led to complete remission of both clinical symptoms and histological findings.

Implications:

  • This case underscores the importance of considering drug-induced causes for eosinophilic colitis.
  • Identifying and removing the offending agent, such as clopidogrel, can effectively manage the condition.